RSSBST Update

BST Position Update – January 8, 2016

BST Position Update – January 8, 2016

| January 8, 2016

. . . . CoLucid Pharmaceuticals (NASDAQ: $CLCD) – Hold  CLCD reached a high of $8.95 this week.  That pushed the gains on this biotech stock to 90% from our buy price. The company is working on a new treatment for migraine headaches.  They are working on the first of two Phase 3 clinical trials. […]

Continue Reading

BST Position Update – December 3, 2015

BST Position Update – December 3, 2015

| December 3, 2015

. . . .  CoLucid Pharmaceuticals (NASD: $CLCD) – Hold  CoLucid Pharmaceuticals is our latest trade.  And it’s good one! CLCD is up 8% today and 45% since we recommended buying it to $6.81. Investors are clearly warming up to the idea that they could have a blockbuster drug on their hands if they can […]

Continue Reading

BST Position Update – November 13, 2015

BST Position Update – November 13, 2015

| November 13, 2015

. . . . Xencor Inc. (NASDAQ: $XNCR) – Hold  Xencor Inc. has announced a research and licensing agreement has been struck with Amgen Inc. $AMGN, for the development and commercialization of novel treatments targeting the areas of cancer immunotherapy and inflammation. Shares of the stock rose 15% after this announcement was made. The company […]

Continue Reading

BST Position Update – November 6, 2015

BST Position Update – November 6, 2015

| November 6, 2015

. . . . Threshold Pharmaceuticals (NASD: $THLD) – Buy  Threshold Pharmaceuticals announced last month that they have received two U.S. patents for Tarloxotinib Bromide, a promising treatment for non-small cell lung cancer and patients with squamous cell cancers of the head and neck or skin. The drug is currently in a Phase 2 clinical […]

Continue Reading

BST Position Update – October 30, 2015

BST Position Update – October 30, 2015

| October 30, 2015

. . . . Verastem (NASD: $VSTM) – Sell  Verastem stock has tanked after announcing they have halted their drug study. The company has stopped a mid-stage study of VS-6063, Verastem’s leading mesothelioma cancer treatment candidate, after studies showed the treatment was not effective enough to warrant any further studies. Let’s cut our losses and […]

Continue Reading

BST Position Update – October 23, 2015

BST Position Update – October 23, 2015

| October 23, 2015

. . . .  Xenor (NASD: $XNCR) – Hold Xenor has just initiated Phase 2 clinical trial of a biological candidate using XmAb Cytotoxix Fc domain for the treatment of asthma and allergic diseases. Xenor has narrowed their current quarter loss from 21 cents a share to 17 cents a share. We are seeing solid […]

Continue Reading

BST Position Update – October 16, 2015

BST Position Update – October 16, 2015

| October 16, 2015

. . . . Anthera Pharmacuticals (NASDAQ: $ANTH) – Buy Anthera currently has three drugs that are in the clinical stage of research, SOLUTION, Chablis-SC, and Bright-SC. Anthera recently announced that they have regained worldwide rights to the drug, Blisibimod, which is being tested in the Chablis-SC study, after ending a partnership with Zanyaku, a […]

Continue Reading

Biotech Market Update – October 2, 2015

Biotech Market Update – October 2, 2015

| October 2, 2015

Biotech Market Update It’s been an ugly week for biotech companies. You may have heard Hillary Clinton’s now infamous tweet, “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on” that sent the market into a tailspin. Overnight, Biotech ETFs were down more than […]

Continue Reading

BST Position Update – September 10, 2015

BST Position Update – September 10, 2015

| September 10, 2015

. . . .  New Link Genetics (NASDAQ: $NLNK) – Buy up to $50.00 NLNK recently announced that their Phase 3 clinical study for VSV-ZEBOV is expected to meet its primary endpoint. It is exciting times for the company, as the vaccine will more than likely end up in consumer hands. This of course also […]

Continue Reading

BST Position Update – August 31, 2015

BST Position Update – August 31, 2015

| August 31, 2015

. . . . Macrocure (NASDAQ: $MCUR) – Sell MCUR recently announced that their Phase 3 clinical study (MC-105) for venous leg ulcers (VLU) is not expected to meet its primary endpoint. Needless to say, that’s a major disappointment given the data they already had going into this clinical trial.  The company is scrambling to […]

Continue Reading